August 06, 2026

The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on Thursday, August 06, 2026

Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time.

We hereby inform you that, the Board of Directors at their meeting held today i.e., on **Thursday, August 06, 2026,** has inter-alia considered and approved the following:

1. The Unaudited Financial Results of the Company for the first quarter ended June 30, 2026. In terms of the above, we enclose herewith the following:
   a. Unaudited Standalone and Consolidated Financial Results of the Company for the first quarter ended June 30, 2026; and
   b. Limited review Reports on the Standalone & Consolidated Financial Results for the first quarter ended 30 June 2026.

The Board Meeting commenced at 18:00 hrs and concluded at 18:45 hrs.

Kindly take the same on record.

Thanking You.

Yours Faithfully
For **Vijaya Diagnostic Centre Limited**

TADEPALLI NAGA VASUDHA

Digitally signed by TADEPALLI NAGA VASUDHA
Date: 2026.08.06 19:17:55 +05'30'

Naga Vasudha Tadepalli
Company Secretary & Compliance Officer
M. No. A23711

Encl.: As above

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075
Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2026

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Unaudited (Refer Note 3 & 6)	Unaudited (Refer Note 6)	Audited (Refer Note 6)
1	**Income**				
	(a) Revenue from operations	21,853.71	20,682.43	17,736.83	76,779.09
	(b) Other income	902.01	724.59	726.08	2,524.15
	Total income	**22,755.72**	**21,407.02**	**18,462.91**	**79,303.24**
2	**Expenses**				
	(a) Cost of materials consumed	2,431.75	2,370.17	2,018.84	8,950.43
	(b) Employee benefits expense	3,489.58	3,141.42	2,946.86	12,154.51
	(c) Finance costs	1,041.78	874.40	691.29	3,082.59
	(d) Depreciation and amortisation expense	2,232.73	2,141.97	1,836.20	8,042.68
	(e) Other expenses	6,468.27	6,019.60	5,716.93	23,284.68
	Total expenses	**15,664.11**	**14,547.56**	**13,210.12**	**55,514.89**
3	**Profit before tax [1 - 2]**	**7,091.61**	**6,859.46**	**5,252.79**	**23,788.35**
4	**Tax expense**				
	(a) Current tax	1,657.34	1,478.61	1,159.63	5,060.45
	(b) Deferred tax	119.51	94.02	188.14	799.71
	Total tax expense	**1,776.85**	**1,572.63**	**1,347.77**	**5,860.16**
5	**Profit for the period/year [3 - 4]**	**5,314.76**	**5,286.83**	**3,905.02**	**17,928.19**
6	**Other comprehensive income**				
	Items that will not be reclassified to profit or loss				
	(a) Remeasurement of defined benefit liability / (asset)	22.88	56.93	(9.58)	83.21
	(b) Income-tax relating to above item	(5.76)	(14.33)	2.41	(20.94)
	Other comprehensive income for the period/year (net of tax)	**17.12**	**42.60**	**(7.17)**	**62.27**
7	**Total comprehensive income for the period/year [5 + 6]**	**5,331.88**	**5,329.43**	**3,897.85**	**17,990.46**
8	**Paid-up equity share capital (Face value of Re. 1 each)**	1,028.97	1,028.97	1,026.88	1,028.97
9	**Other equity (Refer Note 6)**				93,408.32
10	**Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 5)**	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	5.17	5.14	3.80	17.43
	- Diluted (in Rs.)	5.15	5.13	3.79	17.40

Notes:

1. The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 06 Aug 2026.The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2026. An unmodified report has been issued by them thereon.
3. The standalone figures for the quarter ended 31 March 2026 represent the balancing figures between the audited standalone financial results for the full financial year ended 31 March 2026 and the published unaudited year-to-date standalone figures up to the quarter ended 31 December 2025, which were subjected to a limited review.
4. The Company has one operating segment, namely "Diagnostic services" and the information reported to the Chief Operating Decision Maker (CODM) for the purposes of resource allocation and assessment of performance focuses on this operating segment. The Company has disclosed the segment information in the consolidated financial results.
5. During the quarter ended 30 June 2026, the Company has granted 179,500 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee of the Board of Directors at their meeting held on 07 May 2026.
6. The Board of Directors of the Company, at its meeting held on 07 May 2026, approved the acquisition of the business of Medinova Millennium MRI Services LLP ("Transferor Entity"), which is 100% owned by the Company, by way of a slump sale. The transaction has been accounted for in accordance with the pooling of interest method prescribed under Appendix C, Business Combinations of Entities Under Common Control, of Ind AS 103, Business Combinations. Accordingly, the assets, liabilities, reserves and surplus of the Transferor Entity have been recorded by the Company at their existing carrying amounts as appearing in the financial statements of the Transferor Entity after alignment of accounting policies, as applicable. The comparative financial information presented has been restated as if the business combination had occurred from the beginning of the preceding reporting period.
In giving effect to the transaction:
(a) All assets, liabilities, reserves and surplus of the Transferor Entity have been transferred to and vested in Vijaya Diagnostic Centre Limited ("the Company").
(b) The difference between the carrying value of the investment derecognised in the books of the Company and the net assets acquired and reserves and surplus of the Transferor entity has been recognised within Other Equity as "Common control acquisition deficit account".
7. The Board of Directors at its meeting held on 07 May 2026, has proposed and recommended a dividend of Re. 2/- per equity share of Re. 1 each, i.e., 200% for the financial year 2025–26, subject to the approval of the members at the ensuing Annual General Meeting.
8. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUPRITA SURA REDDY
Digitally signed by SUPRITA SURA REDDY
Date: 2026.08.06 19:28:44 +05'30'

S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Hyderabad
Date: 06 August 2026

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Company has accounted for the amalgamation of Medinova Diagnostic Services Limited ("transferor company") with the Company during the quarter and half year ended 30 September 2025 in accordance with the Scheme of Amalgamation approved by the National Company Law Tribunal (NCLT) vide order dated 13 October 2025. The amalgamation has been accounted for by the Company by restating the financial information in the financial results in respect of the prior periods as if it had occurred from the beginning of the preceding year in the financial statements as per the requirement of Indian Accounting Standard.

   The corresponding figures for the quarter ended 30 June 2025, in so far it pertains to the transferor company, have been reviewed by another auditor who had expressed an unmodified conclusion on 26 July 2025.

Our conclusion is not modified in respect of this matter.

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

For **B S R and Co**
Chartered Accountants
Firm's Registration No.:128510W

BALKISHAN KABRA
Digitally signed by BALKISHAN KABRA
Date: 2026.08.06 19:47:28 +05'30'

Balkishan Kabra
Partner
Membership No.: 221202
UDIN:26221202OZTXUL5687

Hyderabad
06 August 2026

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075
Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Audited (Refer Note 3)	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	23,098.19	21,937.67	18,805.31	81,420.19
	(b) Other income	853.03	240.03	704.84	2,079.92
	Total income	**23,951.22**	**22,177.70**	**19,510.15**	**83,500.11**
2	**Expenses**				
	(a) Cost of materials consumed	2,559.62	2,492.73	2,141.27	9,468.44
	(b) Employee benefits expense	3,747.56	3,383.47	3,160.71	13,073.76
	(c) Finance costs	1,100.32	932.38	748.54	3,323.09
	(d) Depreciation and amortisation expense	2,512.23	2,432.84	2,089.01	9,182.44
	(e) Other expenses	6,937.04	6,509.46	6,149.96	25,184.49
	Total expenses	**16,856.77**	**15,750.88**	**14,289.49**	**60,232.22**
3	**Profit before tax [1 - 2]**	**7,094.45**	**6,426.82**	**5,220.66**	**23,267.89**
4	**Tax expense**				
	(a) Current tax	1,657.34	1,479.08	1,159.63	5,067.73
	(c) Deferred tax, net	127.00	154.81	202.13	902.50
	Total tax expense	**1,784.34**	**1,633.89**	**1,361.76**	**5,970.23**
5	**Profit for the period/year [3 - 4]**	**5,310.11**	**4,792.93**	**3,858.90**	**17,297.66**
6	**Other comprehensive income**				
	Items that will not be reclassified to profit or loss				
	(a) Remeasurement of defined benefit liability / (asset)	23.89	60.88	(9.58)	86.89
	(b) Income-tax relating to above item	(6.01)	(15.33)	2.41	(21.87)
	Other comprehensive income for the period/year (net of tax)	**17.88**	**45.55**	**(7.17)**	**65.02**
7	**Total comprehensive income for the period/year [5 + 6]**	**5,327.99**	**4,838.48**	**3,851.73**	**17,362.68**
8	**Paid-up equity share capital (Face value of Re. 1 each)**	1,028.97	1,028.97	1,026.88	1,028.97
9	**Other equity**				94,686.21
10	**Earnings per equity share (Face value of Re. 1 each fully paid up) (Refer Note 5)**	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	5.16	4.66	3.76	16.81
	- Diluted (in Rs.)	5.15	4.65	3.75	16.79

Notes:

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).

2. The above consolidated financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 06 August 2026. The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2026. An unmodified report has been issued by them thereon.

3. The consolidated figures for the quarter ended 31 March 2026 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter ended 31 December 2025, which were subject to limited review.

4. The Group has one operating segment , namely "Diagnostic services" and the information reported to the Chief Operating Decision Maker (CODM) for the purpose of resource allocation and assessment of performance focuses on this operating segment.

(Rs. in Lakhs)

Particulars	For the Three Months ended / As at			For the Year ended / As at
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	Unaudited	Audited	Unaudited	Audited
A. Segment Revenue: Revenue from operations	23,098.19	21,937.67	18,805.31	81,420.19
B. Segment Results: Profit before tax for the period/ year	7,094.45	6,426.82	5,220.66	23,267.89
C. Segment Assets: Total assets	167,693.18	150,704.83	128,642.75	150,704.83
D. Segment Liabilties: Total liabilities	66,490.37	54,989.65	44,611.44	54,989.65

Note: There are no unallocated corporate income / expense / asset and liabilities considering that the Group operates in a single segment.

5. During the quarter ended 30 June 2026, the Company has granted 179,500 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee of the Board of Directors at their meeting held on 07 May 2026.

6. The Board of Directors at its meeting held on 07 May 2026, has proposed and recommended a dividend of Re. 2/- per equity share of Re. 1 each, i.e., 200% for the financial year 2025–26, subject to the approval of the members at the ensuing Annual General Meeting.

7. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUPRITA SURA REDDY
Digitally signed by SUPRITA SURA REDDY
Date: 2026.08.06 19:29:19 +05'30'

S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Hyderabad
Date: 06 August 2026

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

   Parent
   a. Vijaya Diagnostic Centre Limited

   Subsidiaries
   b. VDC Diagnostic (Karnataka) LLP
   c. Medinova Millenium MRI Services LLP
   d. P H Diagnostic Centre Private Limited

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial results of one subsidiary included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 1,280.70 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 27.75 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 28.51 lakhs, for the quarter ended 30 June 2026, as considered in the Statement. These interim financial results has been reviewed by other auditors whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

BALKISHAN KABRA

Digitally signed by BALKISHAN KABRA
Date: 2026.08.06 19:48:05 +05'30'

Balkishan Kabra

Partner

Membership No.: 221202

UDIN:26221202GDAFPE5994

Hyderabad

06 August 2026